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Introduction
Obesity-induced insulin resistance is a major risk factor for type 2 
diabetes, hyperlipidemia, cardiovascular disease, and some types 
of cancer (1–3). Although the mechanism by which obesity causes 
insulin resistance is unclear, inflammation has been linked to the 
development of local and systemic insulin resistance, especially 
when the inflammation occurs in white adipose tissue (WAT) (4, 5).
WAT consists of adipocytes and stromal vascular cells (SVCs) 
including endothelial cells, preadipocytes, and immune cells 
(6). Among the immune cells, macrophages play a particularly 
important role in obesity-induced adipose tissue inflammation. 
Macrophages are classified into 2 types: proinflammatory M1 and 
antiinflammatory M2 macrophages. M1 macrophages express the 
surface marker CD11c (7, 8) and produce proinflammatory cyto-
kines such as TNF-α (9, 10). M2 macrophages express the surface 
marker CD301 and produce antiinflammatory cytokines such as 
IL-10 (7). The relative and absolute number of M1 macrophages 
increases in WAT upon obesity, thereby promoting adipose tissue 
inflammation (7–11). Studies in rodents have suggested that adi-
pose tissue inflammation causes local and systemic insulin resis-
tance (9, 11–13). However, it has been demonstrated that immu-
nocompromised mice are not protected from systemic insulin 
resistance induced by a short-term high-fat diet (HFD) (14). Fur-
thermore, Tian et al. have shown that adipose tissue inflammation 
is dispensable for local and systemic insulin resistance (15). Anoth-
er study has shown that inhibition of adipose tissue inflamma-
tion results in glucose intolerance, suggesting that inflammation 
may even be a mechanism to counter insulin resistance (16). In 
humans, expression of the macrophage markers CD68 and TNF-α 
in WAT correlates with BMI, suggesting that obesity may induce 
the accumulation of adipose tissue macrophages and inflamma-
tion in humans (9, 17). However, clinical trials targeting TNF-α 
have shown little or no beneficial effect on systemic insulin sensi-
tivity (18–21). Thus, the causal relationship between adipose tissue 
inflammation and insulin resistance is unclear.
Two models have been proposed to explain the increase in 
the number of M1 macrophages in WAT upon obesity. The first is 
that circulating monocytes are recruited to WAT, where they dif-
ferentiate into M1 macrophages (7, 22). The second is that obesity 
induces the proliferation of resident macrophages in WAT (23). 
The monocyte chemoattractant protein 1/C-C chemokine ligand 2 
(MCP1/CCL2), presumably produced by adipocytes, is required to 
increase the number of macrophages in WAT (12, 23, 24). Howev-
er, the mechanism(s) controlling MCP1 expression in adipocytes 
upon obesity are poorly understood.
The target of rapamycin complex 2 (TORC2) is an evolution-
arily conserved serine/threonine protein kinase complex that con-
trols growth and metabolism (reviewed in ref. 25). In mammals, 
mTORC2 consists of mTOR, rapamycin-insensitive companion 
of mTOR (RICTOR), mammalian stress-activated protein kinase–
interacting protein 1 (mSIN1), and mammalian lethal with SEC 
thirteen 8 (mLST8) (26–31). Insulin stimulates mTORC2 to pro-
mote glucose uptake in adipose tissue (32–34), liver (35–37), and 
skeletal muscle (38, 39). Previously, we and others have shown 
that adipose-specific Rictor knockout (AdRiKO) exacerbates obe-
sity-related complications in mice, such as systemic insulin resis-
tance and hepatic steatosis (32–34).
Here, we used mTORC2-deficient and therefore insulin-resis-
tant AdRiKO mice to investigate the causal relationship between 
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whether insulin resistance due to impaired insulin/mTORC2 sig-
naling in WAT affects adipose inflammation, we performed quan-
titative proteomics on epididymal WAT (eWAT) from HFD-fed 
(for 10 weeks) AdRiKO (aP2-Cre, Rictorfl/fl) and control (Rictorfl/fl) 
mice. As previously reported (32–34), HFD-fed AdRiKO mice had 
an increased body size with no change in adiposity (Supplemen-
tal Figure 1, A–C; supplemental material available online with 
this article; https://doi.org/10.1172/JCI96139DS1). Furthermore, 
we confirmed that RICTOR expression, AKT (Ser473) phosphor-
ylation, and PKC expression, readouts for mTORC2 signaling, 
were decreased, while S6K  (Thr389) phosphorylation, a readout 
for mTORC1 signaling, was not affected in eWAT (Figure 1B; see 
complete unedited blots in the supplemental material). Among 
approximately 3,000 proteins identified in the proteome, 61 and 
16 were up- and downregulated, respectively, in AdRiKO mice 
insulin resistance and inflammation. We found that inhibition of 
the insulin/mTORC2 pathway resulted in enhanced Mcp1 tran-
scription in mouse and human adipocytes and thereby promoted 
inflammation in visceral WAT. Furthermore, obesity-induced insu-
lin resistance developed before the accumulation of proinflamma-
tory M1 macrophages in visceral WAT of WT mice. Thus, insulin 
resistance precedes and causes inflammation in adipose tissue.
Results
Insulin/mTORC2 signaling in WAT negatively controls inflammation. 
AdRiKO exacerbates systemic insulin resistance upon obesity, as 
evidenced by impaired glucose clearance in response to insulin 
treatment (Figure 1A and refs. 32–34). Thus, the AdRiKO mouse 
is a good model to investigate the causal relationship between 
insulin resistance and inflammation upon obesity. To determine 
Figure 1. Quantitative proteome analysis 
reveals insulin/mTORC2 signaling func-
tions in adipose tissue inflammation. (A) 
ITT for AdRiKO and control mice fed a HFD 
for 10 weeks. Mice were fasted for 5 hours 
prior to the ITT. Data are presented as the 
mean ± SEM. **P < 0.01, ***P < 0.001, and 
****P < 0.0001, by 2-way ANOVA. n = 10 
(control) and n = 5 (AdRiKO). (B) Immuno-
blots of eWAT from HFD-fed AdRiKO and 
control mice. eWAT samples were collect-
ed from ad libitum–fed mice. The same 
lysates were used for proteome analysis. 
(C) Regulated proteome with 3 biological 
replicates. See also Supplemental Table 1.  
(D) GO term analysis of the regulated 
proteome. Data are presented as the  
mean ± SEM.
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of HFD feeding, as measured by insulin-stimulated glucose uptake 
and an insulin tolerance test (ITT) (Figure 3, A and B, and Sup-
plemental Figure 5B), respectively. Mice fed a HFD for 10 weeks 
remained insulin resistant compared with mice on a ND (Figure 
3C and Supplemental Figure 5C). The M1 macrophage population 
in eWAT mildly increased in mice by week 10 of a HFD, but not by 
4 or 8 weeks (Figure 3D). Tnfa expression did not increase in mice 
at 4 or 10 weeks of a HFD (Supplemental Figure 5D). These find-
ings are consistent with previous reports showing that mice devel-
op adipose and systemic insulin resistance within several days to 4 
weeks of a HFD (44, 45), whereas the number of M1 macrophages 
in WAT increases only within 8 to 10 weeks of a HFD (10, 15, 45, 
46). The finding that HFD-induced insulin resistance precedes 
the accumulation of M1 macrophages is consistent with our above 
conclusion that insulin resistance leads to inflammation.
Insulin resistance–induced inflammation is specific to visceral 
WAT. Adipose-specific loss of mTORC2 signaling directly causes 
insulin resistance in all WAT depots and indirectly leads to sys-
temic insulin resistance (32–34). To test whether AdRiKO caus-
es inflammation in liver or in fat depots other than eWAT (see 
above), we examined macrophage numbers in peri-renal WAT 
(prWAT), subcutaneous WAT (sWAT), and liver of HFD-fed 
AdRiKO and control mice. AdRiKO prWAT, but not sWAT or liver, 
had increased numbers of M1 macrophages, (Supplemental Fig-
ure 6, A–C). Thus, AdRiKO promotes inflammation specifically in 
visceral WAT (eWAT and prWAT).
To test whether local insulin resistance causes inflammation 
in the liver, we examined hepatic macrophages in liver-specific 
Rictor-knockout mice (LiRiKO: Alb-Cre, Rictorfl/fl), which have 
hepatic insulin resistance due to loss of insulin/mTORC2 signal-
ing in liver (35–37). HFD-fed LiRiKO mice had a moderate but 
nonsignificant increase in the number of hepatic macrophages 
compared with HFD-fed control mice (Supplemental Figure 6D). 
Furthermore, the numbers of M1 and M2 macrophages in eWAT 
were identical in LiRiKO and control mice (Supplemental Figure 
6E). Thus, the ability of local insulin resistance to promote inflam-
mation is specific to visceral WAT.
Rictor knockout in adipocytes increases expression of the chemo-
kine MCP1. How does insulin resistance in visceral WAT cause 
local accumulation of M1 macrophages and inflammation? Ama-
no et al. have suggested that a HFD induces local proliferation of 
macrophages (23). Alternatively, others have proposed that WAT 
recruits circulating monocytes, which then differentiate into M1 
macrophages (7, 22). To distinguish between these 2 models, we 
used flow cytometry to measure the proliferation marker Ki-67 in 
macrophages in eWAT of HFD-fed mice. The percentage of Ki-67+ 
M1 macrophages in AdRiKO mice was similar to that in control 
mice (Supplemental Figure 7A), suggesting that the increase in M1 
macrophages in AdRiKO eWAT is not due to local proliferation. 
To investigate the possibility that WAT recruits monocytes, we 
examined the expression of WAT-derived chemokines in eWAT 
from HFD-fed AdRiKO and control mice. A chemokine array and 
ELISA revealed increased expression of monocyte chemoattrac-
tant protein 1 (MCP1, also known as C-C motif ligand 2 [CCL2]) in 
AdRiKO eWAT (Figure 4, A and B). Increased levels of MCP1 were 
also detected in the plasma of HFD-fed AdRiKO mice (Figure 4C). 
Furthermore, in SVCs isolated from AdRiKO eWAT, we observed 
compared with controls (Figure 1C and Supplemental Table 1). 
Gene Ontology (GO) analysis of the regulated proteins revealed 
enrichment of immune response–related biological process-
es (Figure 1D), suggesting that insulin resistance due to loss of 
mTORC2 signaling may cause inflammation upon obesity.
To examine further whether mTORC2 in WAT controls 
inflammation, we quantified immune cells in eWAT of HFD-fed 
AdRiKO and control mice by flow cytometry. While the num-
bers of B and T cells did not differ (Supplemental Figure 1D), the 
number of macrophages (F4/80+CD11b+) increased in AdRiKO 
eWAT at 10 weeks of HFD feeding (Figure 2, A and B, and Supple-
mental Figure 2A). The increase in macrophages correlated with 
increased macrophage gene expression (Cd68 and F4/80) and 
F4/80 staining (Figure 2, C and D). Next, we determined whether 
the increase in the number of macrophages in AdRiKO eWAT was 
due to an increase in proinflammatory M1 (F4/80+CD11b+CD11c+) 
and/or antiinflammatory M2 (F4/80+CD11b+CD301+) macro-
phages. The numbers of both M1 and M2 macrophages increased 
in both AdRiKO and control mice during the HFD time course 
(Figure 2, E–G). AdRiKO eWAT showed a disproportionately large 
increase in M1 macrophages, starting at 6 weeks of HFD feeding 
(Figure 2, E and F). Quantification of proinflammatory cytokine 
TNF-α mRNA in SVCs and macrophages isolated from HFD-
fed AdRiKO and control mice confirmed the disproportionate 
increase in M1 macrophages in AdRiKO eWAT (Figure 2, H and I, 
and Supplemental Figure 2, B and C). These observations indicate 
that AdRiKO leads to the accumulation of M1 macrophages, con-
firming that genetically induced insulin resistance due to loss of 
mTORC2 signaling in WAT promotes inflammation. We note that 
there was no difference in macrophage numbers between AdRiKO 
and control mice on a normal diet (ND) (Supplemental Figure 3, 
A–E), indicating that AdRiKO potentiates inflammation only in 
response to obesity.
Our AdRiKO model relies on the adipose-specific promoter 
aP2 to drive Cre expression and thereby knock out Rictor. How-
ever, aP2-Cre can be expressed in cell types other than adipo-
cytes including macrophages (40, 41). Three lines of evidence 
suggest that our findings are not due to confounding effects of 
ectopic knockout of Rictor in macrophages. First, Rictor expres-
sion was unchanged in macrophages isolated from the HFD-fed 
AdRiKO mice compared with those from control mice (Supple-
mental Figure 4, A and B). Second, adipose-specific deletion of 
Rictor via expression of Cre from the Adipoq promoter (i-AdRiKO: 
Adipoq-CreERT2, Rictorfl/fl) (40, 42) also showed an increase in 
M1 macrophages in eWAT upon obesity, as observed in aP2-Cre 
AdRiKO mice (Figure 2, J–M, and Supplemental Figure 4, C and 
D). Third, macrophage-specific knockout of Rictor, due to expres-
sion of Cre from the LysM promoter (LysM-Cre Rictor fl/fl), had no 
effect on macrophages in WAT of mice fed a HFD (43).
HFD-induced insulin resistance precedes the accumulation of adi-
pose tissue M1 macrophages. Our findings indicate that genetically 
induced local insulin resistance causes the accumulation of M1 
macrophages and thus inflammation in WAT upon obesity. This 
predicts that HFD-induced insulin resistance precedes inflamma-
tion in WT mice. To test this prediction, we performed a longitudi-
nal study with HFD-fed WT mice (Supplemental Figure 5A). WT 
mice developed eWAT and systemic insulin resistance by week 4 
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Figure 2. AdRiKO eWAT accumulates M1 macrophages. (A and B) Numbers of  macrophages (CD45+F4/80+CD11b+) in 
SVCs isolated from eWAT of HFD-fed AdRiKO and control mice. Representative FACS profiles are shown in A, and quan-
tification is shown in B. **P < 0.01, by multiple Student’s t test. n = 6–15. (C) Gene expression of macrophage markers 
in eWAT from HFD-fed AdRiKO and control mice. **P < 0.01, by multiple Student’s t test. n = 7–8. (D) Representative 
F4/80 staining of eWAT from HFD-fed AdRiKO and control mice. n = 4. Scale bar: 100 μm. (E–G) Numbers of M1 mac-
rophages (CD45+F4/80+CD11b+CD11c+) and M2 macrophages (CD45+F4/80+CD11b+CD301+) in SVCs from eWAT of HFD-fed 
AdRiKO and control mice. Representative FACS profiles are shown in E, and quantification is shown in F and G.  
****P < 0.0001 and P = 0.053, by multiple Student’s t test. n = 6–15. (H and I) Tnfa gene expression in SVCs (H) (n = 9)  
and isolated macrophages (I) (n = 6–8) from eWAT of HFD-fed AdRiKO and control mice. *P < 0.05, by unpaired 
Student’s t test. (J) Immunoblots of eWAT from i-AdRiKO and control mice. Mice were treated with tamoxifen for 5 
days. After 4 weeks, mice were fasted for 5 hours and then treated with PBS or insulin. (K) ITT for i-AdRiKO and control 
mice 4 weeks after induction of Rictor knockout. Mice were fasted for 5 hours prior to the ITT. **P < 0.01, ***P < 0.001, 
and ****P < 0.0001, by 2-way ANOVA. n = 5 (control) and n = 6 (i-AdRiKO). (L and M) Numbers of M1 macrophages 
(CD45+F4/80+CD11b+CD11c+) (L) and M2 macrophages (CD45+F4/80+CD11b+CD301+) (M) in SVCs from eWAT of HFD-fed 
i-AdRiKO and control mice. *P < 0.05, by unpaired Student’s t test. n = 7. Data are presented as the mean ± SEM.
Downloaded from http://www.jci.org on March 23, 2018.   https://doi.org/10.1172/JCI96139
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5jci.org
autonomous, we first treated 3T3-L1 adipocytes with the mTOR 
inhibitor torin 1 (47). 3T3-L1 adipocytes treated with torin 1 had 
increased Mcp1 expression (Figure 5E). Next, we generated 2 
Rictor-knockout 3T3-L1 adipocyte cell lines (Figure 5F and Supple-
mental Figure 8B) using the genome-editing CRISPR-Cas9 system 
(48). Rictor-knockout 3T3-L1 adipocytes were able to differentiate, 
albeit at a slower rate compared with control cells (Supplemental 
Figure 8C). Consistent with our in vivo data, Mcp1 expression was 
increased in the Rictor-knockout 3T3-L1 adipocytes (Figure 5G 
and Supplemental Figure 8B). Serum and insulin treatment sup-
pressed Mcp1 expression in control but not Rictor-knockout 3T3-L1 
adipocytes (Figure 5H and Supplemental Figure 8D). In WT mice, 
Mcp1 expression increased by 10 weeks, but not 4 weeks, of HFD 
feeding (Supplemental Figure 8E). These data support the notion 
that insulin resistance precedes and promotes Mcp1 transcription 
in adipocytes. We note that Rictor knockout in liver (LiRiKO) did 
not result in hepatic Mcp1 expression (Supplemental Figure 8F), 
consistent with our above finding that LiRiKO failed to stimulate 
inflammation in liver.
How does mTORC2 loss lead to Mcp1 transcription? It has 
been suggested that JNK is required for MCP1 expression and 
secretion in cultured 3T3-L1 adipocytes (49). Consistent with that 
report, treatment with the JNK inhibitor SP600125 reduced Mcp1 
expression in Rictor-knockout 3T3-L1 cells (Figure 5I). Inhibition of 
JNK was confirmed by loss of cJUN (Ser73) phosphorylation (Fig-
ure 5J). SP600125 did not restore AKT (Ser 473) phosphorylation 
(Figure 5J) or insulin-stimulated glucose uptake (Figure 5F) in the 
Rictor-knockout 3T3-L1 cells, indicating that the effect of the drug 
was independent of mTORC2 and insulin resistance. Furthermore, 
JNK activity was unaffected by Rictor knockout (Figure 5, J and K). 
Thus, mTORC2 and JNK control Mcp1 expression independently.
Impaired insulin/mTORC2 signaling and increased MCP1 expres-
sion in omental WAT of obese patients. MCP1 mRNA levels in omen-
tal WAT (oWAT) correlate with BMI in obese human subjects (9, 
50). However, how MCP1 transcription is regulated in human 
adipose tissue is unknown. Our finding that insulin/mTORC2 sig-
significantly increased expression of C-C chemokine receptor 
type 2 (Ccr2), encoding an MCP1 receptor, as a result of increased 
numbers of Ccr2-expressing cells such as monocytes and macro-
phages (Figure 4D). These findings suggest that insulin-resistant 
visceral WAT, via MCP1 expression, recruits monocytes, which 
then differentiate into M1 macrophages.
We next tested whether the increase in MCP1 is responsible 
for M1 macrophage accumulation in AdRiKO eWAT. Mice were 
fed a HFD for 8 weeks and then treated with an MCP1-neutral-
izing or control antibody for 2 weeks along with ongoing HFD 
feeding. The antibody treatments had no impact on body weight 
(Supplemental Figure 7B). The MCP1-neutralizing antibody inhib-
ited the accumulation of M1 macrophages in AdRiKO eWAT by 
50%, with no impact on M2 macrophages (Figure 4E). The MCP1- 
neutralizing antibody also caused a 2-fold increase in monocytes 
(Ly-6ChiCD11b+) in the blood of AdRiKO mice (Figure 4F). Thus, 
MCP1 appears to mediate the increase in M1 macrophages in 
AdRiKO eWAT. Altogether, our data suggest that mTORC2 inhibi-
tion in WAT results in Mcp1 expression, followed by infiltration of 
monocytes in an MCP1-CCR2–dependent manner.
Insulin/mTORC2 signaling inhibits Mcp1 transcription in adipo-
cytes. Expression of the Mcp1 gene was increased in the eWAT of 
HFD-fed AdRiKO and i-AdRiKO mice compared with expression 
levels in control eWAT (Figure 5, A and B), suggesting that MCP1 
is upregulated in AdRiKO WAT at the transcriptional level. Fur-
thermore, we note that the increase in Mcp1 expression (Figure 
5A) coincided with an increase in the number of M1 macrophages 
in AdRiKO eWAT (Figure 2F). The number of macrophages and 
expression levels of Mcp1 were unchanged in AdRiKO and control 
eWAT in ND-fed mice (Supplemental Figure 3 and Supplemen-
tal Figure 8A). To identify the cells in which Mcp1 expression was 
induced, we measured Mcp1 mRNA levels in adipocytes and SVCs 
isolated from eWAT of HFD-fed AdRiKO and control mice (Sup-
plemental Figure 2B). AdRiKO adipocytes, but not SVCs, showed 
increased Mcp1 expression (Figure 5, C and D). To determine 
whether the regulation of Mcp1 transcription by mTORC2 is cell 
Figure 3. HFD-induced insulin resistance 
precedes the accumulation of M1 mac-
rophages. (A) Insulin-stimulated 2DGP 
accumulation in eWAT and muscle from 
WT mice fed a ND or HFD for 4 weeks. Mice 
were fasted for 5 hours, injected with insulin 
at 0 minutes and 2DG at 10 minutes, and 
sacrificed at 30 minutes. ***P < 0.001, by 
unpaired Student’s t test. n = 7–8. (B and 
C) ITT for WT mice fed a ND or HFD for 4 
weeks (B) or 10 weeks (C). Mice were fasted 
for 5 hours prior to the ITT. ****P < 0.0001, 
by 2-way ANOVA. n = 15 (4 wk ND), n = 17 
(4 wk HFD), n = 3 (10 wk ND), and n = 4 (10 
wk HFD). (D) Numbers of M1 macrophages 
(CD45+F4/80+CD11b+CD11c+) and M2 macro-
phages (CD45+F4/80+CD11b+CD301+) in eWAT 
of WT mice fed a HFD for 4, 8, or 10 weeks. 
**P < 0.01, by multiple Student’s t test.  
n = 5–17. Rictorfl/fl mice were used as WT con-
trols. Data are presented as the mean ± SEM.
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naling negatively controls Mcp1 transcription and adipose tissue 
inflammation in mice prompted us to examine insulin/mTORC2 
signaling, MCP1 expression, and macrophage accumulation in 
human visceral WAT, i.e., oWAT. To this end, oWAT samples were 
collected from 20 lean and 30 obese human patients who were 
under general anesthesia (Figure 6A and Supplemental Table 2). 
The obese patients were insulin resistant as determined by high 
homeostatic model assessment of insulin resistance (HOMA-IR) 
(Figure 6B and Supplemental Figure 9A). We note that oWAT 
was collected from patients who, because of standard procedure 
before undergoing general anesthesia, had fasted overnight, a 
condition that might not be optimal for the evaluation of insu-
lin/mTORC2 signaling. Nevertheless, in oWAT, AKT2 (Ser474) 
phosphorylation, a readout for mTORC2 signaling, was lower in 
obese patients than in lean patients (Figure 6, C and D). AKT2 
(Ser474) phosphorylation negatively correlated with BMI (Fig-
ure 6E). These data suggest that insulin/mTORC2 signaling is 
impaired in oWAT of obese and insulin-resistant patients and vali-
date AdRiKO mice as a model for human insulin resistance. MCP1 
expression was higher in obese subjects and positively correlated 
with BMI (Figure 6, F and G, and Supplemental Figure 9B). CD68 
expression was also higher in the obese subjects and positively 
correlated with BMI (Figure 6, H and I, and Supplemental Figure 
9C). MCP1 and CD68 expression levels also correlated (Figure 6J). 
AKT2 (Ser474) phosphorylation did not correlate with MCP1 and 
CD68 expression (Supplemental Figure 9, D and E) when com-
paring the entire cohort of 50 patients, consistent with our above 
observation in mice that inhibition of insulin/mTORC2 signaling 
alone was not sufficient to promote adipose tissue inflammation 
(Supplemental Figure 3). However, approximately one-third of 
the obese patients (9 of 30) had low AKT (Ser474) phosphoryla-
tion and high HOMA-IR, MCP1, and CD68 (Figure 6K), suggest-
ing that AdRiKO mice may phenocopy this subgroup of patients. 
Finally, torin 1 treatment led to an increase in MCP1 expression in 
human primary adipocytes, suggesting that insulin/mTOR signal-
ing inhibits MCP1 expression also in humans (Figure 6, L and M).
Discussion
We provide 2 lines of evidence that insulin resistance promotes 
the accumulation of M1 macrophages and thereby fosters inflam-
mation (Figure 7). First, we show that knockout of mTORC2, i.e., 
genetically induced insulin resistance, in mouse adipocytes dere-
pressed Mcp1 expression. As a consequence, monocytes were 
recruited to visceral WAT, where they differentiated into M1 
macrophages and caused inflammation. Second, HFD-induced 
insulin resistance in WT mice preceded the accumulation of 
proinflammatory M1 macrophages. We also show that oWAT from 
obese, insulin-resistant patients had low mTORC2 signaling, high 
MCP1 expression, and high macrophage content, suggesting that 
our findings in mice have human relevance (Figure 6).
Our findings are consistent with observations made in mice 
genetically modified in other components of the insulin signal-
ing pathway. Two studies demonstrated that deletion of PTEN or 
PIK3R1, negative regulators of insulin signaling, causes enhanced 
insulin sensitivity and a reduced number of macrophages in adi-
pose tissue (51, 52). More recently, Shearin et al. (53) showed that 
Figure 4. Insulin/mTORC2 signaling inhibits Mcp1 transcription and M1 macrophage accumulation in vivo. (A) Adipokine array of eWAT from HFD-fed 
AdRiKO and control mice. Immunoblots show the reduction of RICTOR expression and mTORC2 signaling. n = 8 (data from 8 mice were pooled). (B) MCP1 
protein levels in eWAT from HFD-fed AdRiKO and control mice. *P < 0.05, by unpaired Student’s t test. n = 8. (C) MCP1 protein levels in plasma from 
HFD-fed AdRiKO and control mice. **P < 0.01, by unpaired Student’s t test. n = 8. (D) Ccr2 mRNA levels in SVCs isolated from eWAT of HFD-fed AdRiKO 
and control mice. *P < 0.05, by unpaired Student’s t test. n = 12. (E) Numbers of M1 macrophages (CD45+F4/80+CD11b+CD11c+) and M2 macrophages 
(CD45+F4/80+CD11b+CD301+) in eWAT. Mice were fed a HFD for 8 weeks and treated with a control or MCP1-neutralizing antibody for 2 weeks with ongoing 
HFD feeding. *P < 0.05 and ***P < 0.001, by 1-way ANOVA. n = 5–8. (F) Percentage of inflammatory monocytes in peripheral blood mononuclear cells 
(PBMCs). Mice were treated as in E. **P < 0.01, by 1-way ANOVA. n = 4–7. Data are presented as the mean ± SEM. 
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adipose-specific Akt1- and Akt2-knockout mice exhibit insulin 
resistance and increased macrophage infiltration in adipose tissue.
The above studies altogether may disentangle the “chicken-
and-egg” relationship (see Introduction) of insulin resistance and 
inflammation, at least in adipose tissue. Obesity induces insulin 
resistance, via a yet-to-be defined mechanism, which in turn pro-
motes inflammation. As suggested previously (16), this inflamma-
tion may contribute to adipose tissue remodeling and expansion 
to maintain glucose hemostasis. It has been suggested that acti-
vated M1 macrophages undergo metabolic reprogramming from 
oxidative phosphorylation to glycolysis (54, 55). Thus, a physiolog-
ical role of M1 macrophages could be to clear excess local glucose. 
Our finding that insulin resistance precedes inflammation may 
account for the observation that inhibition of TNF-α is ineffective 
in the treatment of obesity-induced insulin resistance (18–21).
HFD-fed AdRiKO mice showed reduced AKT (Ser473) phos-
phorylation (Figure 1B), decreased glucose uptake (Figure 1A), 
and extensive inflammation (Figure 2) in eWAT. HFD-fed WT 
mice also displayed decreased glucose uptake (Figure 3, A–C), 
which was followed by mild inflammation (Figure 3D). Unexpect-
edly, AKT (Ser473) phosphorylation was not reduced in WT mice 
fed a HFD for 4 or 10 weeks (Supplemental Figure 5, E and F) (56), 
although we still observed mild inflammation in eWAT by week 
10 of HFD feeding. We note that the number of M1 macrophages 
Figure 5. Insulin/mTORC2 signaling inhibits Mcp1 transcription in adipocytes. (A) Mcp1 mRNA levels in eWAT from AdRiKO and control mice during the 
HFD time course. *P < 0.05 and ***P < 0.001, by multiple Student’s t test. n = 5–10. (B) Mcp1 mRNA levels in eWAT from HFD-fed i-AdRiKO and control 
mice. **P < 0.01, by unpaired Student’s t test. n = 4–6. (C and D) Mcp1 mRNA levels in adipocytes (C) and SVCs (D) isolated from eWAT of HFD-fed AdRiKO 
and control mice. ***P < 0.001, by unpaired Student’s t test. n = 13–14. (E) Mcp1 mRNA levels in 3T3-L1 adipocytes treated with DMSO or 250 nM torin 1 for 
6 hours. **P < 0.01, by unpaired Student’s t test. N >3. (F) 2DGP accumulation in insulin-stimulated Rictor-knockout or control 3T3-L1 adipocytes treated 
with DMSO or the JNK inhibitor SP600125 (20 μM). N = 3. (G) Mcp1 mRNA levels in Rictor-knockout and control 3T3-L1 adipocytes. *P < 0.05 and **P < 
0.01, by unpaired Student’s t test. N = 3. (H) Mcp1 mRNA levels in Rictor-knockout and control 3T3-L1 adipocytes treated with or without serum and insu-
lin. *P < 0.05, by unpaired Student’s t test. N = 3. (I) Mcp1 mRNA levels in Rictor-knockout and control 3T3-L1 cells treated with DMSO or the JNK inhibitor 
SP600125 (20 μM) for 6 hours. *P < 0.05 and **P < 0.01, by 1-way ANOVA. N = 3. (J) Immunoblots of Rictor-knockout and control 3T3-L1 adipocytes treated 
with DMSO or the JNK inhibitor SP600125 (20 μM) for 6 hours. N = 3. (K) In vitro JNK kinase assay. Active JNK was immunoprecipitated from Rictor-knock-
out or control 3T3-L1 adipocytes, and JNK activity was assessed toward its substrate cJUN. SP600125 treatment served as a negative control. N = 3. Data 
are presented as the mean ± SEM.
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ity, also functions as a transcriptional repressor (58). We found 
that Lipin1 expression was reduced in Rictor-knockout eWAT and 
adipocytes (Supplemental Figure 10, A and B), suggesting that 
mTORC2 may negatively control Mcp1 transcription via LIPIN1. 
An adipose-specific transcription factor is another candidate 
through which mTORC2 may control Mcp1 expression. Rictor 
knockout increased Mcp1 expression in adipocytes, but not in liv-
er or fibroblasts (Supplemental Figure 8F and Supplemental Fig-
ure 10C), indicating that the regulation of Mcp1 transcription by 
mTORC2 is specific to adipocytes.
Why does AdRiKO eWAT accumulate a disproportionately 
high number of M1 macrophages only in response to obesity? The 
in AdRiKO eWAT was much higher than that in control eWAT 
by week 10 of the HFD (Figure 2F). These findings suggest that 
obesity-induced insulin resistance promotes mild inflammation 
downstream or independently of mTORC2, whereas chronic insu-
lin resistance leads to mTORC2 inhibition and therefore extensive 
inflammation, as observed in AdRiKO mice and obese patients.
Our experiments reveal that loss of mTORC2 leads to 
increased Mcp1 expression in adipocytes (Figure 5). What is the 
downstream effector through which mTORC2 controls Mcp1 tran-
scription? One candidate is the phosphatidic acid phosphatase 
LIPIN1, whose knockdown results in Mcp1 expression in 3T3-L1 
adipocytes (57). LIPIN1, independently of its phosphatase activ-
Figure 6. Impaired insulin/mTORC2 signaling and increased MCP1 expression in oWAT of insulin-resistant obese patients. (A and B) BMI and HOMA-IR 
of lean and obese patients. ***P < 0.001 and ****P < 0.0001, by Mann-Whitney U test. See also Supplemental Table 2. (C) Representative immunoblots 
for p-AKT2 (Ser474) and AKT2 in human oWAT. (D) Quantification of p-AKT2 (Ser474) normalized to total AKT2. ***P < 0.001, by Mann-Whitney U test. 
(E) p-AKT2 (Ser474)/AKT2 negatively correlated with BMI. Significance was determined by Pearson’s correlation analysis. (F) MCP1 mRNA levels in human 
oWAT. **P < 0.01, by Mann-Whitney U test. (G) MCP1 positively correlated with BMI. Significance was determined by Pearson’s correlation analysis. (H) 
CD68 mRNA levels in human oWAT. **P < 0.01, by Mann-Whitney U test. (I and J) CD68 positively correlated with BMI (I) and MCP1 levels (J). Significance 
in I and J was determined by Pearson’s correlation analysis. (K) Cluster analysis of BMI, HOMA-IR, p-AKT2 (Ser474)/AKT2, MCP1, and CD68 levels. (L and M) 
Effect of torin 1 on insulin/mTORC2 signaling (L) and MCP1 mRNA levels (M) in human primary adipocytes. Differentiated human primary adipocytes were 
treated with DMSO or 250 nM torin 1 for 6 hours.
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trol. For i-AdRiKO mouse experiments, control mice were also treated 
with tamoxifen. Mice were randomly assigned for each experiment. 
Only male, 6- to 16-week-old mice were used for experiments.
Cell culture. 3T3-L1 cells were cultured and differentiated as 
described previously (62). In brief, 3T3-L1 preadipocyte cells were 
maintained in M1 medium (DMEM supplemented with 4 mM gluta-
mine, 1 mM sodium pyruvate, 1× penicillin and streptomycin, and 10% 
FBS) at 37°C in an incubator with 5% CO2. For differentiation, cells 
were maintained in M1 medium for 2 days after reaching confluence. 
The medium was replaced with M2 medium (M1 medium supple-
mented with 1.5 μg/ml insulin, 0.5 mM IBMX, 1 μM dexamethasone, 
and 2 μM rosiglitazone), defined as day 0 of differentiation. After 2 
days, the medium was replaced with M3 medium (M1 with 1.5 μg/ml 
insulin). The medium was replaced with M2 on day 4 of differentia-
tion. From day 6, cells were maintained in M3 with a medium change 
every 2 days. For all experiments, cells differentiated for 10 to 14 days 
were used. Torin 1 was purchased from Tocris Bioscience and dis-
solved in DMSO.
Human oWAT biopsies. oWAT biopsies were obtained from lean 
subjects with a BMI below 27 kg/m2 and from obese subjects with a 
BMI above 35 kg/m2 (Supplemental Table 2). Patients were fasted 
overnight and then underwent general anesthesia. All oWAT samples 
were obtained between 8:30 and 12:00, snap-frozen in liquid nitro-
gen, and stored at –80°C.
Human primary adipocytes. Human primary visceral preadipo-
cytes (from a 56-year-oldwoman with a BMI of 23) were obtained from 
Lonza. Cells were cultured and differentiated according to the man-
ufacturer’s instructions. After 14 days of differentiation, cells were 
treated with DMSO or 250 nM torin1 for 6 hours.
Generation of Rictor-knockout cells by CRISPR/Cas9-mediat-
ed genome editing. Rictor-knockout 3T3-L1 cells (Hall laboratory 
stock) were generated using the CRISPR/Cas9 system. Oligonucle-
otides containing single-guide RNAs (sgRNAs) (Rictor.1, forward: 
CACCGGAAGATACTGATCCCGCTTG, sgRNA Rictor.1, reverse: 
AAACCAAGCGGGATCAGTATCTTCC; sgRNA Rictor.2, forward: 
CACCGTGCCTCCTAGGGCTTGGTCG, sgRNA Rictor.1, reverse: 
AAACCGACCAAGCCCTAGGAGGCAC) were cloned into lenti-
CRISPRv2 (Addgene plasmid 52961) (48), a gift of Feng Zhang (MIT, 
Cambridge Massachusetts, USA). Plasmids were amplified by bacte-
rial transformation and isolated by Miniprep (Zymo Research). Lenti-
CRISPRv2 plasmids were cotransfected with psPAX2 (Addgene plas-
mid 12260; a gift of Didier Trono, EPFL, Lausanne, Switzerland) and 
pCMV-VSV-G (63) (Addgene plasmid 8454; a gift of Robert Weinberg, 
MIT, Cambridge, Massachusetts, USA) into HEK293T cells (Hall lab-
oratory stock). Supernatants containing lentiviruses were collected 1 
day after transfection and used to transduce undifferentiated 3T3-L1 
cells. Transduced cells were selected by puromycin.
2-Deoxyglucose uptake assay. Mice were fed a ND or HFD for 4 
weeks, fasted for 5 hours, and given Humalog insulin i.p. (Lilly; 0.75 
U/kg body weight). After 10 minutes, 2-deoxyglucose (2DG) (Sigma- 
Aldrich) was given i.p. (32.8 μg/g body weight), and tissues (eWAT, 
muscle) were collected 20 minutes later. For in vitro 2DG uptake, 
differentiated adipocytes were cultured in serum-free M1 medium, 
washed 3 times with HKRP buffer (1.2 mM KH2PO4, 1.2 mM MgSO4, 
1.3 mM CaCl2, 118 mM NaCl, 5 mM KCl, and 30 mM HEPES, pH7.5), 
and cultured in HKRP buffer with 1% BSA for 30 minutes. Cells were 
stimulated with 100 nM insulin for 20 minutes and subsequently 
increase in Mcp1 transcription in mTORC2-knockout adipocytes 
required JNK activity (Figure 5I), which is high only in WAT from 
obese mice (59, 60). Thus, obesity might be a prerequisite for JNK 
activation, which in turn stimulates Mcp1 expression in conjunc-
tion with loss of mTORC2. We note that mTORC2 did not control 
JNK (Figure 5, J and K).
In summary, we propose that obesity-mediated insulin resis-
tance is a cause of inflammation in visceral WAT. Although our 
findings do not rule out the possibility that inflammation promotes 
insulin resistance in other tissues or conditions, they bring into 
question whether antiinflammation therapy in adipose tissue is an 
effective strategy in the prevention of type 2 diabetes.
Methods
Mice. Adipose tissue–specific Rictor-knockout (AdRiKO) and liver- 
specific Rictor-knockout (LiRiKO) mice were described previously (32, 
35, 61). Since AdRiKO mice are infertile, we bred Rictorfl/+ aP2-Cre mice 
with Rictorfl/fl mice to generate mice for our experiments. For experi-
ments with AdRiKO mice, age-matched Cre-negative males were used 
as controls. To generate LiRiKO mice for experiments, Rictorfl/fl Alb-Cre 
mice were crossed with Rictorfl/fl mice. To generate an i-AdRiKO mouse 
line, Rictorfl/fl mice were bred with adipoq-CreERT2 mice, provided by 
Stefan Offermanns (Max Planck Institute for Heart and Lung Research 
[MPI-HLR], Bad Nauheim, Germany) (42). Once the i-AdRiKO mouse 
line (Rictorfl/fl adipoq-CreERT2) was generated, these mice were bred 
with Rictorfl/fl mice to produce mice for experiments. For experiments 
with LiRiKO and i-AdRiKO mice, Cre-negative littermate male mice 
were used as controls. All mice used in this study were on a C57BL/6 
background. For i-AdRiKO mice, Rictor knockout was induced by i.p. 
injection of 1 mg/mouse tamoxifen (Sigma-Aldrich) resuspended in 
corn oil daily for 5 days. Mice were housed at 22°C in a conventional 
facility under a 12-hour light/12-hour dark cycle with unlimited access 
to water and were fed a ND or a HFD (60% kcal from fat NAFAG 2127, 
KLIBA). The HFD-feeding experiment was conducted for 10 weeks 
unless otherwise specified. Cre-negative animals were used as a con-
Figure 7. Insulin resistance causes inflammation in adipose tissue. Insulin 
resistance, due to obesity and loss of insulin/mTORC2 signaling, results in 
enhanced production of MCP1 in adipocytes.  MCP1 in turn recruits mono-
cytes and activates proinflammatory M1 macrophages.
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CD301–Alexa Fluor 647 (AbD Serotec; catalog MCA2392A647T); 
CD4-FITC (eBioscience; catalog 11-0041-81); CD8a-PE (eBioscience; 
catalog 12-0081-81); CD3-APC (eBioscience; catalog 17-0032-80); 
CD45R (B220) PerCP-Cyanine 5.5 (eBioscience; catalog 45-0452-
80); CD25 APC-eFluor 780 (eBioscience; catalog 47-0251-80); and 
Ki-67–Alexa Fluor 488 (BD Pharmingen; catalog 561165), along with 
a FOXP3 Flow Kit (BioLegend, catalog 320021) and a Live/Dead Fix-
able Dead Cell Kit (Thermo Fisher; catalog L34955). Stained SVCs 
were analyzed using the FACSCanto II (BD Biosciences) or sorted 
with a FACSAria IIIu (BD Biosciences).
Immunohistochemistry. WATs were fixed overnight in 4% formalin 
at room temperature, dehydrated, embedded in paraffin, and cut into 
5-μm-thick sections. Adipose tissue macrophages were stained with 
anti-F4/80 antibody (Abcam; catalog ab6640) and a secondary anti-
body conjugated with HRP (VECTOR Laboratories), followed by incu-
bation in ImmPACT DAB peroxidase substrate solution (VECTOR 
Laboratories) and subsequent counterstaining with hematoxylin 
(VECTOR Laboratories). Images were obtained using DM600B (Lei-
ca) and analyzed with Fiji software (ImageJ; NIH) (65).
RNA isolation and quantitative real-time PCR. Total RNA was 
isolated with TRIzol Reagent (Sigma-Aldrich) and an RNeasy Kit 
(QIAGEN). For RNA isolation from sorted macrophages, an RNeasy 
Micro Kit (QIAGEN) was used. RNA was reverse transcribed to cDNA 
using an iScript cDNA Synthesis Kit (Bio-Rad). Semiquantitative real-
time PCR analysis was performed using Fast SYBR Green (Applied 
Biosystems). Relative expression levels were determined by normal-
izing each Ct value to either Polr2a, Tbp, or Rpl7 expression for mice 
and RNA18S5 for human samples using the ΔΔCt method. The primer 
sequences used in this study are shown in Table 1.
Protein isolation and immunoblots. Tissues were homogenized in 
lysis buffer containing 100 mM Tris-HCl, pH7.5, 2 mM EDTA, 2 mM 
EGTA, 150 mM NaCl, 1% Triton X-100, cOmplete Inhibitor Cock-
tail (Roche), and PhosSTOP (Roche). The protein concentration was 
determined by the Bradford assay, and equal amounts of protein were 
separated by SDS-PAGE and transferred onto nitrocellulose mem-
branes (GE Healthcare). The following antibodies were used in this 
study and were purchased from Cell Signaling Technology: AKT (cat-
alog 4685); phosphorylated AKT (p-AKT) (Ser473) (catalog 4060), 
RICTOR (catalog 2140), PKC (catalog 2056), p-S6K (Thr389) (catalog 
9234), S6K (catalog 2708), p-JNK (Thr183/Tyr185) (catalog 4668), 
JNK (catalog 9252), p-cJUN (Ser73) (catalog 3270), cJUN (catalog 
9165). Actin monoclonal antibody was purchased from Sigma-Aldrich 
(catalog MAB1501).
JNK kinase assay. JNK activity was measured using a SAPK/JNK 
Kinase Assay Kit (Nonradioactive) (Cell Signaling Technology; cat-
alog 8794).
Proteome analysis. eWAT was homogenized in urea lysis buffer 
containing 50 mM Tris-HCl, pH 8.2, 8 M urea, 75 mM NaCl, cOm-
plete inhibitor cocktail (Roche), and PhosSTOP (Roche). The extracts 
were incubated for 30 minutes at 4°C and centrifuged for 15 minutes 
at 14,000 g. Protein concentration was measured with the Bradford 
assay. Proteins were reduced with 2.5 mM DTT for 40 minutes at 56°C 
and alkylated with 7.5 mM iodoacetamide for 40 minutes at room tem-
perature in the dark with gentle shaking. The urea concentration was 
lowered to 4 M with 25 mM Tris-HCl, pH 8. The lysates were digested 
with 2 rounds of endoproteinase LysC (Wako) at an enzyme/protein 
ratio of 1:100 (w/w) at 37°C for 2 hours. After the LysC digestion, the 
cultured with 1 mM 2DG for 20 minutes. Tissues or cells were lysed 
in 10 mM Tris-HCL, pH 8.0, by boiling for 15 minutes. 2-Deoxyglu-
cose-6-phosphate (2DGP) was measured using a Glucose Uptake-Glo 
Assay Kit (Promega) following the manufacturer’s instructions.
MCP1 ELISA and adipokine array. Mice were fed a HFD for 10 
weeks, and MCP1 levels in eWAT and plasma were measured using 
a commercial ELISA kit (R&D Systems) following the manufacturer’s 
instructions. Adipokine array (R&D Systems) was performed accord-
ing to the manufacturer’s instructions.
MCP1-neutralizing antibody treatment. Mice were fed a HFD for 8 
weeks. Mice were given i.p. 1 mg/kg body weight isotype control IgG 
(BD Biosciences; catalog 553968, lot 4113848) or anti–MCP1 IgG (BD 
Biosciences; catalog 554440, lot 5203535) every 2 days for 2 weeks.
ITT. Mice were fasted for 5 hours, Humalog insulin (Lilly) was 
given i.p. (0.75U/kg body weight), and blood glucose levels were mea-
sured with an Accu-Chek blood glucose meter.
In vivo insulin stimulation. Mice were fasted for 5 hours, Humalog 
insulin (Lilly) was administered i.p. (0.75U/kg body weight), and tis-
sues were collected.
Isolation of adipocytes and SVCs and flow cytometric analysis. SVCs 
were isolated and stained with antibody as previously described (64). 
In brief, fat pads were excised and minced in HBSS++ supplemented 
with 0.5% BSA and digested with 1 mg/ml type II collagenase (Sigma- 
Aldrich) at 37°C for 40 minutes with vigorous shaking. After digestion, 
final 10 mM EDTA was added and incubated for 10 minutes to disso-
ciate SVCs. The resulting suspension was filtered through a 100-μm 
cell strainer (Corning) and centrifuged at 500 g for 10 minutes. After 
centrifugation, floating adipocytes were collected, and SVC-contain-
ing pellets were subjected to red blood cell lysis in 1× Red Blood Cell 
Lysis Buffer (eBioscience). SVCs were blocked with Fc-block (BD 
Biosciences) and stained with the following antibodies and reagents: 
F4/80-PE (eBioscience; catalog 12-4801-80); CD11b-APC eFluor 780 
(eBioscience; catalog 47-0112-80); CD11c-PE-Cy7 (eBioscience; cat-
alog 25-0114-81); CD45.2-PerCP (eBioscience; catalog 45-0454-80); 
Table 1. qRT-PCR primers
Species Target Forward primer Reverse primer
Mouse Cd68 TATAGCCCAAGGAACAGAGGAA CTGTAGGTGTCATCGTGAAGG
F4/80 TTGCGGGATTCCTACACTATCT AGGTTTCTCACCATCAGGAAGA
Tnfa GGTTCTGTCCCTTTCACTCA TGCCTCTTCTGCCAGTTCC
Rictor ATGGCCAATATCGCAAAGAAG GTGGCCAAATTGCAAGGAGTA
Cd11c GGATGGACTGGTGGATCTGG GGTGTGAAGTGAACAGTTGGTG
Mcp1 CTACCTTTTCCACAACCACCTC ATTAAGGCATCACAGTCCGAGT
Lep TCACACACGCAGTCGGTATC ACTCAGAATGGGGTGAAGCC
Adipoq TGACGACACCAAAAGGGCTC ACGTCATCTTCGGCATGACT
Cd31 TGCTCTCGAAGCCCAGTATT ATGGGTGCAGTTCCATTTTC
Cd45 CCAGTGATGAACTGAGCACAAC TTGGGGGTGTGGATTCAGTG
Cd3g CTTCAAGGCACTGTAGCCCA GTACAGAACCGTCTCCTCGG
Polr2a AATCCGCATCATGAACAGTG CAGCATGTTGGACTCAATGC
Tbp TGCTGTTGGTGATTGT CTTGTGTGGGAAAGAT
Rpl7 CGGTCTCTTGGTAAGTTTGGC TTGAAGCGTTTCCCGACTGT
Human MCP1 CCGAGAGGCTGAGACTAACC CTTTCATGCTGGAGGCGAGA
CD68 ACAGGGAATGACTGTCCTCAC TGCTCTCTGTAACCGTGGGT
RNA18S5 GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
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Progenesis data file. The data aligned in Progenesis were exported 
as .txt files to the R-based Perseus program (68). Volcano plots and 
ANOVA 2-sample t tests were performed with a FDR of 5%. Proteins 
were considered regulated when the ANOVA 2-sample t test was 
below 0.05 in each technical replicate and the Student’s t test P value 
was below 0.05 in at least 2 of 3 biological replicates. GO process anal-
ysis was performed according to the framework provided by the Gene 
Ontology Consortium (69, 70).
Statistics. Immunoblots for p-AKT2 (Ser474) and AKT2 on human 
oWAT were quantified in Fiji (65). Samples for which we failed to 
detect AKT2 were excluded from further analysis. Sample size was 
chosen according to our previous studies and published reports in 
which similar experimental procedures were described. The investi-
gators were not blinded to the treatment groups. All data are shown 
as the mean ± SEM. Sample numbers are indicated in each figure 
legend. For mouse experiments, n represents the number of animals, 
and for cell culture experiments, N indicates the number of indepen-
dent experiments. To determine the statistical significance between 2 
groups, an unpaired 2-tailed Student’s t test was performed. For more 
than 3 groups, 1-way ANOVA was performed. For ITT data, 2-way 
ANOVA was performed. For human samples, statistical outliers were 
excluded in Figure 6 according to the robust regression and outlier 
removal test (ROUT) (Q = 1%) but are included in Supplemental Fig-
ure 9. In all cases, a Mann-Whitney U test was performed to deter-
mine statistical significance. All statistical analysis was performed 
using GraphPad Prism 7 (GraphPad Software). Cluster analysis was 
performed using ClustVis (71). A P value of less than 0.05 was consid-
ered statistically significant.
Study approval. All animal experiments were performed in 
accordance with federal guidelines for animal experimentation 
and approved by the Kantonales Veterinäramt of the Kanton Basel-
Stadt (Basel, Switzerland). For human biopsies, the study protocol 
was approved by the Ethikkomission Nordwest-und Zentralschweiz 
(EKNZ) (Basel, Switzerland). All patients provided informed consent 
to provide adipose tissue samples.
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urea concentration was lowered to 1 M with 25 mM Tris-HCl, pH 8.0. 
The lysates were digested with 2 rounds of trypsin (Worthington) at 
an enzyme/protein ratio of 1:100 (w/w) for 2 hours, followed by over-
night digestion at 37°C. Digestion was stopped by adding trifluoro-
acetic acid (TFA) to reach a final concentration of 0.4%. The digests 
were centrifuged for 5 minutes at 3,000 g and desalted on a C18 Sep-
Pak cartridge (Waters) that had been equilibrated with 0.1% TFA. The 
peptides were applied onto the cartridge, washed with 0.1% TFA, and 
subsequently eluted with 0.5% AcOH/80% AcCN. The peptide con-
centration was estimated by measuring the UV absorbance at 280 nm 
(66). The desalted peptides were dried in a SpeedVac (Thermo Fisher 
Scientific). For strong cation separation, the dried peptides were dis-
solved in 1.5 ml 7 mM KH2PO4, pH 2.65, and 30% AcCN (v/v) (SCX 
buffer A) and centrifuged at 10,600 × g. The peptides were applied 
onto a HiTrap SP cartridge (GE Healthcare) that had been equilibrated 
with 3 ml SCX buffer A, and the cartridge was washed with 3 ml SCX 
buffer A. Bound peptides were stepwise eluted with 1.5 ml each of SCX 
buffer A containing 50 mM, 100 mM, 150 mM, 250 mM, and 350 mM 
KCl, and each fraction was collected manually. The peptide concen-
tration was estimated by absorbance at 280 nm. The fractions were 
dried in a SpeedVac and desalted on either micro or macro spin C18 
columns (The Nest Group). The peptides were desalted with 0.1% TFA 
and subsequently eluted with 0.5% AcOH/80% AcCN. The dried pep-
tides (20 μg) were dissolved in 20 μl of 0.1% formic acid and 0.005% 
TFA and analyzed on an Orbitrap Elite FT Hybrid Instrument (Ther-
mo Fisher Scientific).
The peptides from the SCX step-off fractions were analyzed by 
capillary liquid chromatography tandem MS (LC-MS/MS) using a 
home-packed separating column (0.075 mm × 15 cm) packed with 
Reprosil C18 reverse-phase material (2.4 m particle size; provided 
by Albin Maisch, Ammerbuch-Entringen, Germany). The column 
was connected online to an Orbitrap Elite FT Hybrid Instrument. 
The solvents used for peptide separation were 0.1% formic acid in 
water/0.005% TFA (solvent A) and 0.1% formic acid/0.005% TFA 
and 80% acetonitrile in water (solvent B). Peptide digest (2 μl) was 
injected with a Proxeon nLC Capillary Pump (Thermo Fisher Scien-
tific) set to 0.3 μl/min. A linear gradient from 0% to 40% of solvent B 
in solvent A in 95 minutes was delivered with the nano pump at a flow 
rate of 0.3 μl/min. After 95 minutes, the percentage of solvent B was 
increased to 75% in 10 minutes. The eluting peptides were ionized at 
2.5 kV. The mass spectrometer was operated in data-dependent mode. 
The precursor scan was done in the Orbitrap, set to 60,000 resolu-
tion, while the fragment ions were mass analyzed in the LTQ Orbitrap 
Instrument. A top-10 method was run so that the 10 most intense pre-
cursors were selected for fragmentation. Each biological replicate was 
measured in 3 technical replicates.
The LC-MS/MS data were searched with Proteome Discov-
erer 1.4 (Thermo Fisher Scientific), set to Mascot and Sequest HT 
against a mouse UniProtKB databank (67). The precursor tolerance 
was set to 10 ppm, while the fragment ion tolerance was set to 0.5 
Da. The following variable modifications were used during the 
search: carbamidomethyl-cystein, oxidized methionine, and N-ter-
minal protein acetylation. The peptide search matches were set at 
“high confidence” (1% FDR).
All LC-MS/MS runs were aligned with Progenesis software 
(Waters). For identification of the aligned features, the corresponding 
Proteome Discoverer 1.4 results files were imported into the aligned 
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